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and Stewart G Martin1,4*Abstract
Background: Pancreatic cancer, including cancer of the ampulla of Vater and bile duct, is very aggressive and has a
poor five year survival rate; improved methods of patient stratification are required.
Methods: We assessed the expression of calpain-1, calpain-2 and calpastatin in two patient cohorts using
immunohistochemistry on tissue microarrays. The first cohort was composed of 68 pancreatic adenocarcinomas
and the second cohort was composed of 120 cancers of the bile duct and ampulla.
Results: In bile duct and ampullary carcinomas an association was observed between cytoplasmic calpastatin
expression and patient age (P = 0.036), and between nuclear calpastatin expression and increased tumour stage
(P = 0.026) and the presence of vascular invasion (P = 0.043). In pancreatic cancer, high calpain-2 expression was
significantly associated with improved overall survival (P = 0.036), which remained significant in multivariate
Cox-regression analysis (hazard ratio = 0.342; 95% confidence interva l = 0.157-0.741; P = 0.007). In cancers of the
bile duct and ampulla, low cytoplasmic expression of calpastatin was significantly associated with poor overall
survival (P = 0.012), which remained significant in multivariate Cox-regression analysis (hazard ratio = 0.595; 95%
confidence interval = 0.365-0.968; P = 0.037).
Conclusion: The results suggest that calpain-2 and calpastatin expression is important in pancreatic cancers,
influencing disease progression. The findings of this study warrant a larger follow-up study.
Keywords: Calpain, Calpastatin, Pancreas, Ampulla, Bile duct, CancerBackground
Pancreatic cancer is an aggressive disease with a poor
prognosis, with a five year survival rate of 6% in the
United States [1]. Although advances in surgery and
adjuvant chemotherapy have improved survival rates
most patients present with advanced inoperable
disease, with poor clinical outcome despite chemother-
apy. Chemotherapy in advanced biliary tract cancer
improves survival, but the overall prognosis remains
poor [2]. The expression of a number of proteins has
been shown to be associated with poor survival of* Correspondence: stewart.martin@nottingham.ac.uk
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reproduction in any medium, provided the orpatients with pancreatic cancer, including expression of
epidermal growth factor receptor (EGFR), insulin-like
growth factor-1 receptor (IGF-1R) [3], heat shock
protein-27 (HSP27) [4] and VEGF [5]. The role for ad-
juvant chemotherapy remains unclear in cholangiocar-
cinomas and ampullary tumours; hence there is
an urgent need to develop biomarkers to allow perso-
nalised treatments for patients with pancreaticobiliary
tumours [6,7]. The calpain system is a family of
cysteine proteases, with micro (μ)-calpain and milli
(m)-calpain being the most widely studied [8]. Both
μ-calpain and m-calpain are heterodimers, each sharing
a 28kDa regulatory subunit (CAPNS1) and having indi-
vidual 80kDa catalytic subunit (calpain-1 (CAPN1) and
calpain-2 (CAPN2) respectively). The archetypical
family members, μ-calpain and m-calpain, were named
on the basis of the concentration of calcium ions
required for activation in-vitro [8]. There are severald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2407/12/511mechanisms which can promote calpain activity by
reducing the concentration of calcium ions required
for activation; these include autolysis of the catalytic
subunit, interaction with phospholipids, and phos-
phorylation [9-11]. Calpastatin (CAST) is the ubiqui-
tously expressed inhibitor of μ-calpain and m-calpain,
which requires calcium-induced structural changes to
μ-calpain and m-calpain for its inhibitory action
[12,13].
Many of the precise physiological functions of the cal-
pain family of enzymes remain to be elucidated. In experi-
mental models calpain has been shown to influence cell
motility and apoptosis, and as such is implicated in
tumour progression and the response of tumour cells to
various treatment modalities, including chemotherapy and
targeted therapies [14]. Altered expression of the catalytic
subunits of μ-calpain and m-calpain, and calpastatin has
been described in a number of tumour types including
breast cancer [15,16]. The expression of μ-calpain, m-
calpain and calpastatin has not been previously examined
in pancreatic, ampullary or bile duct cancers, however, a
single nucleotide polymorphism of calpain-10 (CAPN10)
has been associated with an increased risk of developing
pancreatic cancer in smokers [17]. In normal pancreaticTable 1 Associations between calpastatin, calpain-1 and calpa
variables in the pancreatic cancer cohort
Calpain-1 Calpain-2
Low High p value Low High
Age
≤ 60 years (n=23) 17 (34.7) 4 (30.8) 1.000* 3 (18.8) 18 (37.5)
> 60 years (n=45) 32 (65.3) 9 (69.2) 13 (81.3) 30 (62.5)
Tumour size
≤ 2cm (n=17) 16 (33.3) 1 (7.7) 0.088* 5 (31.3) 12 (25.5)
> 2cm (n=50) 32 (66.7) 12 (92.3) 11 (68.8) 35 (74.5)
T stage
2 (n=12) 6 (12.2) 3 (23.1) 0.335 2 (12.5) 9 (18.8)
3 (n=54) 42 (85.7) 9 (69.2) 14 (87.5) 37 (77.1)
4 (n=2) 1 (2.0) 1 (7.7) 0 (0.0) 2 (4.2)
N stage
Negative (n=22) 17 (35.4) 4 (33.3) 1.000* 3 (18.8) 18 (39.1)
Positive (n=44) 31 (64.6) 8 (66.7) 13 (81.3) 28 (60.9)
Vascular invasion
absent (n=24) 19 (38.8) 4 (30.8) 0.751* 3 (18.8) 20 (41.7)
present (n=44) 30 (61.2) 9 (69.2) 13 (81.3) 28 (58.3)
Perineural invasion
absent (n=14) 8 (16.3) 5 (38.5) 0.122* 1 (6.3) 12 (25.0)
present (n=54) 41 (83.7) 8 (61.58) 15 (93.8) 36 (75.0)
The frequency of observed clinicopathological variables is noted next to the variabl
are resultant from Pearson Chi Square test of association (χ2) or Fisher’s Exact test in
are indicated by bold font.tissue calpain has been implicated in a number of func-
tions including calcium induced insulin secretion and β-
cell spreading [18]. Furthermore, an altered balance be-
tween calpastatin and calpain has been implicated in acute
pancreatitis in rats [19]. The aims of the current study
were to investigate the expression levels of calpastatin,
and of the catalytic subunits of μ-calpain and m-calpain in
tumours from pancreatic, bile duct and ampullary cancer
patients. Furthermore we aimed to determine the import-
ance of expression in terms of associations with clinico-
pathological variables and clinical outcome.
Methods
Clinical samples
Investigation of calpain-1, calpain-2 and calpastatin was
conducted using a tissue microarray with tissue
collected from patients treated at Nottingham Univer-
sity Hospitals between 1993 and 2010. This study has
ethical approval from the Nottingham Research Ethics
Committee. This study was conducted according to
REMARK criteria [20]. 68 patients with pancreatic
adenocarcinoma who underwent surgical resection were
included in the study. 65% of patients were male
(44/68) and the age of the patients ranged from 35in-2 protein expression and various clinicopathological
Calpastatin (cytoplasmic) Calpastatin (nuclear)
p value Low High p value Low High p value
0.225* 16 (32.0) 4 (33.3) 1.000* 15 (33.3) 5 (29.4) 1.000*
34 (68.0) 8 (66.7) 30 (66.7) 12 (70.6)
0.747* 13 (26.5) 3 (25.0) 1.000* 10 (22.7) 6 (35.3) 0.317
36 (73.5) 9 (75.0) 34 (77.3) 11 (64.7)
0.576 8 (16.0) 3 (25.0) 0.380 8 (17.8) 3 (17.6) 0.766
41 (82.0) 8 (66.7) 36 (80.0) 13 (76.5)
1 (2.0) 1 (8.3) 1 (2.2) 1 (5.9)
0.220* 15 (30.6) 5 (45.5) 0.481* 14 (31.8) 6 (37.5) 0.760*
34 (69.4) 6 (54.5) 30 (68.2) 10 (62.5)
0.136* 19 (38.0) 4 (33.3) 1.000* 15 (33.3) 8 (47.1) 0.318
31 (62.0) 8 (66.7) 30 (66.7) 9 (52.9)
0.157* 11 (22.0) 2 (16.7) 1.000* 10 (22.2) 3 (17.6) 1.000*
39 (78.0) 10 (83.3) 35 (77.8) 14 (82.4)
e subgroup; one case did not have available data for tumour size. The P values
a 2×2 table if a cell count was less than 5 (indicated by *). Significant P values
Table 2 Associations between calpastatin, calpain-1 and calpain-2 protein expression and various clinicopathological
variables in the bile duct and ampullary cancer cohort
Variable Calpain-1 Calpain-2 Calpastatin (cytoplasmic) Calpastatin (nuclear)
Low High p value Low High p value Low High p value Low High p value
Age
≤ 60 years (n=40) 12 (30.0) 27 (38.6) 0.366 14 (36.8) 22 (34.9) 0.845 16 (50.0) 22 (28.9) 0.036 25 (35.7) 12 (32.4) 0.734
> 60 years (n=78) 28 (70.0) 43 (61.4) 24 (63.2) 41 (65.1) 16 (50.0) 54 (71.1) 45 (64.3) 25 (67.6)
Tumour size
≤ 2cm (n=48) 15 (37.5) 29 (40.8) 0.729 18 (46.2) 21 (33.3) 0.195 17 (51.5) 27 (35.5) 0.118 30 (42.3) 13 (35.1) 0.473
> 2cm (n=70) 25 (62.5) 42 (59.2) 21 (53.8) 42 (66.7) 16 (48.5) 49 (64.5) 41 (57.7) 24 (64.9)
T stage
1 (n=3) 0 (0.0) 3 (4.2) 0.262 0 (0.0) 3 (4.7) 0.137 1 (3.0) 2 (2.6) 0.918 0 (0.0) 3 (8.1) 0.026
2 (n=27) 11 (26.8) 13 (18.3) 7 (17.9) 15 (23.4) 8 (24.2) 17 (22.1) 20 (27.8) 5 (22.9)
3 (n=86) 28 (68.3) 54 (76.1) 30 (76.9) 46 (71.9) 23 (69.7) 57 (74.0) 50 (69.4) 29 (78.4)
4 (n=3) 2 (4.9) 1 (1.4) 2 (5.1) 0 (0.0) 1 (3.0) 1 (1.8) 2 (2.8) 0 (0.0)
N stage
Negative (n=44) 14 (35.9) 28 (41.2) 0.590 14 (37.8) 24 (39.3) 0.882 11 (35.5) 30 (40.5) 0.628 26 (38.2) 15 (41.7) 0.733
Positive (n=69) 25 (64.1) 40 (58.8) 23 (62.2) 37 (60.7) 20 (64.5) 44 (59.5) 42 (61.8) 21 (58.3)
Vascular invasion
absent (n=52) 18 (43.9) 30 (42.9) 0.915 18 (47.4) 26 (40.6) 0.506 13 (39.4) 34 (44.7) 0.605 36 (50.0) 11 (29.7) 0.043
present (n=66) 23 (56.1) 40 (57.1) 20 (52.6) 38 (59.4) 20 (60.6) 42 (55.3) 36 (50.0) 26 (70.3)
Perineural invasion
absent (n=51) 17 (41.5) 32 (45.1) 0.711 16 (41.0) 30 (46.9) 0.562 15 (45.5) 34 (44.2) 0.900 36 (50.0) 12 (32.4) 0.080
present (n=68) 24 (58.5) 39 (54.9) 23 (59.0) 34 (53.1) 18 (54.5) 43 (55.8) 36 (50.0) 25 (67.6)
Tumour site
Proximal bile duct (n=5) 3 (7.3) 1 (1.4) 0.251 1 (2.6) 3 (4.7) 0.418 3 (9.1) 1 (1.3) 0.074 4 (5.6) 0 (0.0) 0.288
Distal bile duct (n=65) 22 (53.7) 38 (53.5) 24 (61.5) 31 (48.4) 19 (57.6) 39 (50.6) 39 (54.2) 19 (51.4)
Ampullary (n=50) 16 (39.0) 32 (45.1) 14 (35.9) 30 (46.9) 11 (33.3) 37 (48.1) 29 (40.3) 18 (48.6)
The frequency of observed clinicopathological variables is noted next to the variable subgroup; in some instances data was not available, 2 cases for patient age,
2 cases for tumour size: 1 case for tumour stage, 7 cases for N stage, 2 cases for vascular invasion, and 1 case for perineural invasion. The P values are resultant
from Pearson Chi Square test of association (χ2) or Fisher’s Exact test in a 2×2 table if a cell count was less than 5 (indicated by *). Significant P values are
indicated by bold font.
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pathological criteria of the cohort are shown in Table 1.
120 patients with bile duct and ampullary tumours were
also included in this study. 54.2% of patients were male
(65/120) and the age of the patients ranged from 38
years to 76 years with a median age of 64. The clinico-
pathological criteria of the cohort are shown in Table 2.
For both patient cohorts survival was calculated from
the date of surgery to the date of death, or from the
date of surgery to the last date known to be alive for
those patients censored. The median survival time was
22.5 months for pancreatic adenocarcinomas and 19.6
months for bile duct and ampullary tumours. In the
pancreatic cohort 46.9% (23/49) of patients received ad-
juvant chemotherapy (data was not available for 19
patients), of the 23 patients that did receive adjuvant
chemotherapy 78.3% (18/23) received 5FU/folinic acid
and 21.7% (5/23) received gemcitabine chemotherapy.In the bile duct and ampullary cohort 24.6% (17/69) of
patients received adjuvant chemotherapy (data was not
available for 51 patients), of the 17 patients that did
receive adjuvant chemotherapy 76.5% (13/17) received
5FU/folinic acid and 23.5% (4/17) received gemcitabine
chemotherapy in the context of clinical trials. The op-
erative intention was curative and patients with suspected
involvement of the portal vein following assessment by
radiology did not receive surgery. In the pancreatic cohort
82% (56/68) of patients had whipple surgery, 10% (7/68)
of patients had a distal pancreatectomy and 7% (5/68) of
patients had a total pancreatectomy. In the ampulla and
bile duct cohort 98% (110/112) of patients had whipple
surgery and 2% (2/112) of patients had a total pancreatec-
tomy. In the pancreatic cohort 44.1% (30/68) of patients
had satisfactory margins following surgery (R0) and 55.9%
(38/68) of patients had margins that were compromised
(R1). In the ampulla and bile duct cohort 64.7% of patients
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of patients had compromised margins (R1).
Tissue microarray and immunohistochemistry
The tissue microarray (TMA) was prepared using triplicate
0.6mm tissue cores of tumour, identified by a specialist
pathologist, placed into a single recipient paraffin block.
4μm sections of the TMA were mounted on poly-L-lysine
coated slides. Immunohistochemistry was performed on
the TMA slides which were initially deparaffinised in xylene
followed by rehydration in ethanol. Antigen retrieval was
performed in 0.01molL-1 sodium citrate buffer (pH6) in
a microwave; 450W for 10 minutes. Endogenous
peroxidase activity was blocked over 10 minutes in 0.01%
hydrogen peroxide in methanol. Primary antibodies; mouse
anti-calpastatin (1:15,000), mouse anti-calpain-1 (1:2500)
and rabbit anti-calpain-2 (1:2500) (all Chemicon,
Massachusetts, USA, clones PI-11, P-6 and rabbit poly-
clonal AB1625 respectively with specificity confirmed byFigure 1 Representative photomicrographs of protein expression. A-C
absence of immunoreactivity in papillary pancreatic adenocarcinoma; B: str
cholangiocarcinoma; C: staining in mucinous secreting adenocarcinoma. D
immunoreactivity in poorly differentiated adenocarcinoma; E: moderate cyt
adenocarcinoma; F: weak dot cytoplasmic immunoreactivity in pancreatic a
absence of immunoreactivity in moderately differentiated adenocarcinoma
adenocarcinoma; I: staining in mucinous secreting adenocarcinoma. Photo
where scale bar shows 100μm.Western blotting) were diluted in blocking serum and
applied to the tissue for one hour at room temperature.
Staining was achieved using the Vectastain Elite ABC kit
(universal), containing blocking serum, biotinylated second-
ary antibody and ABC reagent (Vector Laboratories,
Peterborough, UK). Immunohistochemical reactions were
developed with 3,3’ diaminobenzidine as the chromogenic
peroxidase substrate (Dako, Glostrup, Denmark). Sections
were then counterstained with Gills formula Haematoxy-
lin (Vector Laboratories), dehydrated and fixed in xylene
prior to mounting with DPX. Breast tumour composite
sections which comprised of 6 stage 1 breast tumours of
grade 1 to 3 were included as positive and negative
controls with each run, with the negative control having
primary antibody substituted for PBS. All cores were
assessed semi-quantitatively using an immunohistochem-
ical H-score using a Nikon Eclipse E600 at 200x magnifi-
cation. Staining intensity was assessed as; none (0), weak
(1), medium (2) and strong (3) over the percentage area of: calpastatin staining in pancreatic and distal cholangiocarcinoma; A:
ong cytoplasmic immunoreactivity in moderately differentiated
-F: calpain-1 staining in pancreatic carcinoma; D: absence of
oplasmic and nuclear staining in moderately differentiated
denocarcinoma. G-I: calpain-2 staining in pancreatic carcinoma; G:
; H: moderate cytoplasmic and nuclear activity in poorly differentiated
micrographs are at 10x magnification with 20x magnification inset box
Figure 2 Kaplan-Meier analysis of progression-free survival showing the impact of calpain-1 (panel A), calpain-2 (panel B), cytoplasmic
calpastatin (panel C) and nuclear calpastatin (panel D) expression in the pancreatic cancer cohort with significance determined using
the log rank test.
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plying the percentage area by the intensity grade (H score
range 0–300). Each core was assessed by two individuals,
including one pathologist and a consensus agreed. An aver-
age H-score was generated by taking the mean H-score of
the three cores available for each patient.Statistical analysis
The relationship between categorised protein expression
and clinicopathological variables was assessed using
Pearson Chi Square (χ2) test of association. Survival curves
were plotted according to the Kaplan-Meier method and
significance determined using the log-rank test. Multivari-
ate survival analysis was performed by Cox Proportional
Hazards regression model. All differences were deemed
statistically significant at the level of P<0.05. Statistical ana-
lysis was performed using SPSS 19.0 software (IBM Corpor-
ation, NY, USA). Stratification cut-points were determinedusing X-Tile software (Yale School of Medicine, CT, USA)
and were determined prior to statistical analyses [21].
Results
Staining location and frequency
Calpain-1 and calpain-2 demonstrated cytoplasmic staining
with some granularity and heterogeneity between adjacent
tumour cells, varying from weak to intense staining with a
few instances of calpain-2 nuclear staining (Figure 1).
Calpastatin stained both the cytoplasm and nucleus of
tumour cells. In the pancreatic adenocarcinoma cohort
calpain-1 had a median H-score of 140 and ranged from 0
to 280; calpain-2 had a median H-score of 118 and ranged
from 10 to 293; cytoplasmic calpastatin expression had a
median H-score of 188 and ranged from 0 to 300 and nu-
clear calpastatin expression had a median H-score of 54
and ranged from 0 to 300. The X-tile cut point for calpain-
1 was 200, calpain-2 was 80, cytoplasmic calpastatin was
285 and nuclear calpastatin was 110; with 21.0% (13/62),
Table 3 Cox proportional hazards analysis for overall
survival in the pancreatic cancer cohort (A) and the bile
duct and ampullary cancer cohort (B) for calpain-2 and
calpastatin expression respectively
A
p value Exp(B) 95.0% CI for Exp(B)
Lower Upper
Calpain 2 expression 0.007 0.342 0.157 0.741
Sex 0.042 2.136 1.029 4.433
T stage 0.672 1.242 0.456 3.380
Node status 0.224 1.642 0.738 3.653
Vascular invasion 0.683 0.868 0.439 1.715
Perineural invasion 0.946 1.030 0.434 2.442
Grade 0.211 1.481 0.801 2.741
Tumour size 0.017 2.929 1.209 7.098
Patient age 0.332 0.709 0.353 1.421
B
p value Exp(B) 95.0% CI for Exp(B)
Lower Upper
Cytoplasmic calpastatin 0.037 0.595 0.365 0.968
T stage 0.083 1.525 0.946 2.459
Perineural invasion 0.388 1.251 0.752 2.083
Grade 0.124 1.422 0.908 2.225
Exp (B) is used to denote hazard ratio, and 95% CI is used to denote 95%
confidence interval.
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http://www.biomedcentral.com/1471-2407/12/51175.0% (48/64), 19.4% (12/62), and 27.4% (17/62) respect-
ively having high protein expression. In the bile duct and
ampullary carcinoma cohort calpain-1 had a median
H-score of 100 and ranged from 0 to 270; calpain-2 had a
median H-score of 50 and ranged from 0 to 200; cytoplas-
mic calpastatin expression had a median H-score of 137
and ranged from 0 to 300 and nuclear calpastatin expres-
sion had a median H-score of 20 and ranged from 0 to 210.
The X-tile cut point for calpain-1 was 70, calpain-2 was 50,
cytoplasmic calpastatin was 103 and nuclear calpastatin
was 40; with 63.4% (71/112), 62.1% (64/103), 70.0%
(77/110), and 33.9% (37/109) respectively having high pro-
tein expression. The correlation between expression of the
proteins with each other was assessed using the Spearman
rank correlation coefficient. In the pancreatic cohort
calpain-1 expression had a statistically significant correl-
ation, but of marginal biological importance, with calpain-2
expression (r=0.281, P=0.026), cytoplasmic calpastatin
expression (r=0.327, P=0.010), and nuclear calpastatin
expression (r=0.346, P=0.006). No correlation was observed
between calpain-2 expression and cytoplasmic or nuclear
calpastatin expression. Cytoplasmic expression of calpasta-
tin was strongly correlated with nuclear calpastatin expres-
sion (r=0.824, P<0.001). In the bile duct and ampullary
carcinomas calpain-1 expression had a statistically signifi-
cant correlation with cytoplasmic calpastatin expression(r = 0.425, P < 0.001) and nuclear calpastatin expression
(r = 0.295, P = 0.002), but not with calpain-2 expression.
Calpain-2 expression was correlated with cytoplasmic
calpastatin expression (r = 0.250, P = 0.009) but not nuclear
calpastatin expression. Cytoplasmic expression of calpasta-
tin was strongly correlated with nuclear calpastatin expres-
sion (r = 0.665, P < 0.001).
Clinicopathological criteria
The expression of calpain-1, calpain-2 and calpastatin
cytoplasmic and nuclear expression was tested to determine
associations with clinicopathological criteria in the pancre-
atic and the grouped bile duct and ampullary cancers. No
associations were observed between marker expression and
pancreatic adenocarcinomas (Table 1). In the bile duct and
ampullary carcinomas an association was observed between
high cytoplasmic calpastatin expression and patients aged
above 60 years (χ2=4.376, d.f.=1, P=0.036). In addition an
association between high nuclear calpastatin expression
and increased tumour stage (χ2=9.303, d.f.=3, P=0.026) and
the presence of vascular invasion (χ2=4.093, d.f.=1,
P=0.043) (Table 2).
Relationship with clinical outcome
In pancreatic cancer calpain-2 was significantly associated
with overall survival (P = 0.036) (Figure 2, panel A), which
remained significant in multivariate Cox-regression analysis
(Hazard Ratio (HR) = 0.342; 95% Confidence Interval
(95% CI) = 0.157-0.741; P = 0.007) (Table 3 panel A). In the
multivariate Cox-regression the potential confounding fac-
tors of patient sex (P = 0.119) and age (P = 0.683), tumour
size (P = 0.086), grade (P = 0.824), stage (P = 0.677), lymph
node status (P = 0.127), perineural and vascular invasion
(P = 0.152 and P = 0.449) were included; none of these
parameters were significantly associated with survival. In
cancers of the bile duct and ampulla, low cytoplasmic ex-
pression of calpastatin was significantly associated with
poor overall survival (P = 0.012) (Figure 3, panel C), which
remained significant in multivariate Cox-regression analysis
(HR = 0.595; 95% CI = 0.365-0.968; P = 0.037) (Table 3
panel B). In the multivariate Cox-regression the potential
confounding factors of tumour stage, perineural invasion
and tumour grade were included (with individual Kaplan-
Meier statistics of P = 0.037, P =0.041 and P = 0.048 re-
spectively). When the ampullary and bile duct cohort was
separated to cancers of the ampulla and cancers of the
proximal and distal bile duct, low calpastatin expression
was associated with survival in the ampullary cancers only
(P = 0.043). Resection margin was available for both the
pancreatic and ampulla and bile duct cohorts, however was
not included in multivariate analysis as it was not signifi-
cantly associated with survival (P = 0.912 and P = 0.446 re-
spectively); similar results were observed for adjuvant
chemotherapy, with adjuvant chemotherapy not associated
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pulla and bile duct cohort (P=0.430).
Discussion
This study examined the expression of calpain-1
(μ-calpain catalytic subunit), calpain-2 (m-calpain
subunit) and calpastatin in cancers of the pancreas,
bile duct and ampulla using immunohistochemistry.
No associations were observed between protein
expression of the calpain system and clinicopatholo-
gical criteria of the pancreatic adenocarcinoma
cohort. In the bile duct and ampulla carcinoma co-
hort a significant association was observed between
high cytoplasmic calpastatin expression and patients
aged above 60 years and high nuclear calpastatin ex-
pression and increased tumour stage and the pres-
ence of vascular invasion. An association between
low cytoplasmic calpastatin expression and the
presence of lymphovascular invasion, encompassingFigure 3 Kaplan-Meier analysis of progression-free survival showing t
calpastatin (panel C) and nuclear calpastatin (panel D) expression in t
determined using the log rank test.invasion of both lymphatic and blood vessels has
been reported in breast cancer [15]. It is interesting
to note that the current results show a high fre-
quency of calpastatin expression within the nucleus,
that has not previously been observed in other
tumour types, such as breast cancer [15]. Perineural
aggregation of calpastatin has been reported in brain
cells, whereby aggregation serves as an intracellular
store of the inhibitor prior to its release into the
cytosol [22]. Furthermore there is evidence to sug-
gest that nuclear translocation of calpastatin occurs
in experimental models [23,24]. It is unclear as to
why this would occur more often in cancers of the
pancreas, bile duct and ampulla. The calpain system,
including calpastatin, is implicated in tumour pro-
gression through its role in multiple cell pathways
including cellular migration, apoptosis and cell sur-
vival [14]. There is little information in pancreatic,
bile duct or ampullary cancers regarding calpainhe impact of calpain-1 (panel A), calpain-2 (panel B), cytoplasmic
he bile duct and ampullary cancer cohort with significance
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morphisms in calpain-10 (CAPN10) have been asso-
ciated with pancreatic cancer in smokers [17]. In this
study low calpain-2 expression was associated with ad-
verse overall survival in the pancreatic cancer cohort
(P=0.036), which remained significant in multivariate
analysis (P=0.007). This was perhaps unexpected as pre-
vious findings in breast cancer have indicated that high
calpain expression is associated with poor survival [16].
It is unclear why low levels of calpain-2 expression are
associated with poor survival outcome, although it may
be due to numerous factors such as the tumour type,
the chemotherapy treatment or lack thereof, or simply
the nature of the organ. A further important aspect to
note is that this study describes the protein expression
of calpain-1 and calpain-2 and not the relative calpain
activity levels. Determining the activity of calpain may
be possible as part of future studies, using antibodies
against calpain specific degradation products; however
such reagents require further validation in human ma-
lignancies such as cancer [25,26]. In the bile duct and
ampullary cancer cohort, low cytoplasmic calpastatin
expression was associated with adverse overall sur-
vival (P=0.012), which remained significant in multi-
variate analysis (P=0.037). In the ampulla and bile
duct cohort only tumour stage, grade and perineural
invasion was associated with survival and included in
the multivariate analysis; this may be due to the earl-
ier presentation of cancers in comparison to pancre-
atic adenocarcinoma due to the manifestation of
clinical symptoms. Low calpain expression would be
expected to allow a higher level of calpain activity, how-
ever in cases where low expression of calpastatin was
observed, low calpain-1 and calpain-2 protein expression
was observed. As previously stated this study determined
the protein expression level of calpain-1 and calpain-2 and
as such the finding that low calpastatin expression is
linked with low calpain-1 and calpain-2 expression may
suggest that protein expression and activity of the
enzymes are somewhat discordant.
In summary, this study demonstrates that low expres-
sion of calpain-2 is associated with poor survival in pan-
creatic cancer and low cytoplasmic calpastatin expression
is associated with poor survival in cancers of the bile duct
and ampulla. The associations observed between protein
expression and adverse survival outcome remained signifi-
cant in multivariate analysis. Determining expression of
the calpain system may be of benefit in patients with pan-
creatic, bile duct of ampullary cancers. The findings of this
study warrant a larger follow-up study with increased
numbers of patients.Competing interest
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